VENATORX PHARMACEUTICALS INC — Department of Health and Human Services SBIR Phase II: NIAID
VENATORX PHARMACEUTICALS INC — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $3,462,890, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Topic code NIAID links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $3,462,890
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NIAID
- Solicitation
- PAR14-088
- NAICS
- —
- Place of performance
- PA
- Period
- 2016-07-05 → 2019-06-30
Description
DESCRIPTIONprovided by applicantNovel therapies for the treatment of Chikungunya virusCHIKVinfections are urgently needed to address the alarming spread of this pathogen across the AmericasWe have identified a series of potentselectiveand orally bioavailable inhibitors of CHIKV replicationIn this Direct to Phaseprojectwe will optimize this series of CHIKV inhibitors to Pre Development stage and advance a first ever CHIKV antiviral candidate to IND enabling studiesTo accomplish this taskwe will execute an integrated medicinal chemistry optimization biological profiling campaign to optimize the potencydrug like properties and oral exposure of the seriesOne or more Pre Development Candidates will be identified and advanced through candidate selection studies into non GLP repeat dose tox in both rats and dogs